Ryoncil e amohetsoe bakeng sa kalafo ea steroid-refractory acute graft-versus-host disease (SR-aGVHD), boemo bo sokelang bophelo bo ka bakoang ke ho fetisoa ha lisele tsa mali ho nkang sebaka sa lisele tse nang le bokooa tsa moamoheli mefuteng e itseng ea mofets'e oa mali. , mathata a mali kapa mathata a tsamaiso ea 'mele ea ho itšireletsa mafung. Sena se etsa hore Ryoncil e be phekolo ea pele e amohetsoeng ke FDA ea MSC (Mesenchymal Stem Cell). Ryoncil e na le li-MSC tse arohaneng le moko oa masapo a batho ba baholo ba phetseng hantle ba fanang ka liphallelo tse ka khethollang mefuta e meng e mengata ea lisele. Ho tšeloa ka methapo ea lisele tsa mesenchymal stromal (MSCs) ho fana ka melemo ea ho phela.
Ka la 18 Tšitoe 2024, FDA e amohelehang Ryoncil (remestemcel-L-rknd), phekolo ea allogeneic (donor) e entsoeng ka masapo a mesenchymal stromal cell (MSC) bakeng sa phekolo ea steroid-refractory acute graft-versus-host disease (SR-aGVHD) ho bakuli ba bana ba likhoeli tse peli. ya dilemo le ho feta. Sena se etsa hore Ryoncil e be phekolo ea pele e amohetsoeng ke FDA ea MSC (Mesenchymal Stem Cell).
Ryoncil e na le li-MSC tse arohaneng le moko oa masapo a batho ba baholo ba phetseng hantle ba fanang ka liphallelo tse ka khethollang mefuta e meng e mengata ea lisele.
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) ke boemo bo tebileng le bo sokelang bophelo bo ka bang le liphello tse kholo, tse pharaletseng tsa bophelo bo botle, ho kenyelletsa le tšenyo ea litho tse ngata, ho fokotsa boleng ba bophelo le kotsi ea lefu ho ba amehileng. bakuli. Sena se ka etsahala e le complication ea allogeneic hematopoietic (mali) stem cell transplantation (allo-HSCT).
Ho allo-HSCT, mokuli o fumana lisele tsa "hematopoietic stem" ho tsoa ho mofani ea phetseng hantle ho nka sebaka sa lisele tsa bona tsa 'mele le ho theha lisele tse ncha tsa mali, e leng mokhoa o atisang ho etsoa e le karolo ea phekolo ea mefuta e itseng ea kankere ea mali, mathata a mali kapa tsamaiso ea' mele ea ho itšireletsa mafung.
Kamohelo ea Ryoncil e latela tlhahlobo ea polokeho le katleho ea eona phuputsong ea litsi tse ngata, ea letsoho le le leng e amang barupeluoa ba 54 ba bana ba nang le SR-aGVHD ba neng ba fetile allo-HSCT. Barupeluoa ba fumane kakaretso ea li-infusions tse robeli tsa Ryoncil habeli ka beke bakeng sa libeke tse 'ne tse latellanang. Tlhahlobo ea katleho e ne e thehiloe haholo-holo ho tekanyo le nako ea ho arabela kalafo matsatsi a 28 ka mor'a ho qala Ryoncil.
Tekong e 'ngoe bakeng sa SR-aGVHD ka mor'a allo-HSCT, ho ile ha fumanoa hore motsoako oa MSCs le basiliximab (monoclonal antibody e sebelisetsoang ho thibela ho hana transplant) e lebisa ho tekanyo e ntle haholo e feletseng ea karabo (CR) ho feta basiliximab feela.
Ho 'nile ha hlokomeloa litekong tsa bongaka hore li-infusions tsa IV tsa lisele tsa mesenchymal stromal (MSCs) li fana ka melemo ea ho pholoha.
***
References:
- Phatlalatso ea Litaba tsa FDA - FDA e Amohela Phekolo ea Pele ea Mesenchymal Stromal Cell ho Phekola Mafu a Acute Graft-versus-host a Steroid-refractory. E ngotsoe ka la 18 Tšitoe 2024. E fumaneha ho https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host
- Fu, H., Sun, X., Lin, R. et al. Lisele tsa Mesenchymal stromal hammoho le basiliximab li ntlafatsa karabelo ea lefu la steroid-refractory acute graft-versus-host e le kalafo ea moleng oa bobeli: liteko tse ngata, tse sa reroang, tse laoloang. BMC Med 22, 85 (2024). https://doi.org/10.1186/s12916-024-03275-5
- Kelly, K., Bloor, AJC, Griffin, JE et al. Liphetho tsa ts'ireletso ea lilemo tse peli tsa li-cell-derived mesenchymal stromal cell in acute steroid-resistant graft-versus-host disease. Nat Med 30, 1556–1558 (2024). https://doi.org/10.1038/s41591-024-02990-z
***
